cagrilintide novo Nordisk's share plunges 19.5% post release of weight loss drug CagriSema's trial results Cagrilintide 5mg - OP Labs
Cagrilintide 5mg OP Labs (Formerly Oxford Peptides) Novo Nordisk's stock drops despite CagriSema hitting goal of Phase III trial Clinical Trials Arena Data on Novo Nordisk experimental weight loss drug show mostly mild side effects Reuters Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints Reuters
Pay in 4 interest-free payments of $7.28 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14



